Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis - 14/02/22
Highlights |
• | All studies compared Bamlanivimab monotherapy vs. control group. |
• | A total of 8 studies comprising of 13,573 adult patients with COVID-19 were included. |
• | Outcomes suggested Bamlanivimab improved hospitalization and mortality rates. |
Keywords : COVID-19, Bamlanivimab, Mortality, SARS-Cov-2
Plan
Vol 84 - N° 2
P. 248-288 - février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.